MRTX News and Press, Mirati Therapeutics Inc. From 04/16/20

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Buy rating and $60 (33% upside) price target at Jefferies. More news on: ACADIA Pharmaceuticals Inc., eHealth, Inc., Lumos Pharma, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

As the health crisis spirals into a financial one, the liquidation and panic selling have indiscriminately hit sectors across the board. The biotechs were no exception, with the S&P Biotech ETF ( XBI ) plummeting -20% on the year in tandem with the S&P 500 (SPY). Source: WingCapital...

Allakos (NASDAQ: ALLK ) initiated with Underperform rating and $34 (42% downside risk) price target at SMBC Nikko. More news on: Allakos Inc., Avadel Pharmaceuticals plc, Krystal Biotech, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

The only way of catching a train I have ever discovered is to miss the train before .”― G.K. Chesterton Markets continue to plunge on increasing worries around the outbreak of the coronavirus. The rise of Bernie Sanders in the polls as noted on CNBC are also not helpin...

Mirati Therapeutics (NASDAQ: MRTX ): Q4 GAAP EPS of -$1.83 misses by $0.40 . More news on: Mirati Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year-ended December 31, 2019 . "In 2019, we advanced MRTX849, our KRAS G12C inhibitor in...

SAN DIEGO , Feb. 19, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical stage targeted oncology company, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 26,712 shares of common stock and an aggregate of 16,659 re...

SAN DIEGO , Feb. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in combination with nivolum...

Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...

Researchers at BMO Financial Group have initiated coverage of four companies in the biotech space, with one gaining an “outperform” rating. In an email to clients sent on Tuesday (January 28), the bank confirmed that its research analyst George Farmer will now cover BioMarin Ph...